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Abstract	1
2
Objective: Intraoperative detection of ovarian sentinel nodes has been shown to be feasible. We examined3
the detection rate and locations of sentinel nodes in patients with ovarian tumors. We also aimed to assess4
the reliability of sentinel node method in predicting regional lymph node metastasis.5
Methods: Twenty patients scheduled for laparotomy due to a pelvic mass were recruited to the study. In6
the beginning of the laparotomy, radioisotope and blue dye were injected under the serosa next to the7
junction of the ovarian tumor and suspensory ligament. The number and locations of the hot and/or blue8
nodes/spots were recorded during the operation. If the tumor was malignant according to the frozen9
section, systematic lymphadenectomies were performed, the sentinel nodes sampled separately and their10
status compared to other regional lymph nodes.11
Results: Eleven patients had a right-sided ovarian tumor, 7 patients a left-sided tumor and 2 patients12
bilateral tumors. A median of 2 sentinel nodes/locations per patient (range 1-3) were found. Sixty percent13
of all SNs were located in paraaortic region only, compared to 30 % in both paraaortic and pelvic areas and14
10 % in pelvic area only. Both uni- and bilateral locations were found.  In 83 % of the cases with more than15
one sentinel node location, they were located in separate anatomical regions. In three patients, systematic16
lymphadenectomies were performed. One of them had nodal metastases in two regions and also a17
metastasis in one of her two sentinel nodes in one of those regions.18
19
20
21
Conclusions: In patients with ovarian tumor(s), the detection of sentinel nodes is feasible. They are located 
in different anatomic areas both ipsi- and contralaterally, although most of them are found in the 
paraaortic region. The reliability of the sentinel node concept should be evaluated in the framework of a 
multicenter trial.22
23
24
25
26
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Introduction	29
30
Pelvic and paraaortic lymphadenectomy is considered to be a mandatory part of surgical care in early31
ovarian cancer. Accurate surgical staging is associated with better prognosis, provided that at least 1032
nodes are harvested from different and specific retroperitoneal sites; especially paraaortic/paracaval nodes33
between the inferior mesenteric artery and the renal vein, superficial iliac nodes and nodes from the34
obturator fossa (1). Morever, larger number of removed nodes increases the likelihood of finding more35
lymph node metastasis (2). On the other hand, the increasing extend of the lymphadenectomy carries36
increasing risk of of serious complications (1), the blood loss and proportion of patients transfused, the37
duration of the surgery and the length of hospital stay (3).38
During the surge of mini-invasive surgery in gynecological cancer, sentinel node (SN) concept has been39
adopted into surgery of early vulvar, cervical and endometrial cancer (4). In early ovarian cancer (EOC), the40
concept has been mainly overlooked because of a laborious reachability of the intra-abdominal injection41
site, a presumption of the slowness of commonly used tracers and a fear of spillage of tumor cells following42
the injection.43
In 2011, Nyberg et al. reported a successful intraoperative use of blue dye and technetium isotope in44
detection of ovarian SNs after tracer injection into a normal postmenopausal ovary in patients with high-45
risk uterine cancer. The SN detection rate during systematic lymphadenectomies in a series of 16 patients46
was 94 %, and all SNs were located in the paraaortic regions (5). Three years later, Kleppe et al. described47
that the use of blue dye and radioisotope in ovarian tumor patients was successful in finding SN locations in48
all of their 21 patients. They injected the tracers into two sites in ovarian ligaments outside the suspicious49
tumor to prevent any potential dissemination of cancer cells. After injection, they located the hot SN sites50
transperitoneally with a gamma detector and retroperitoneally, if the tumors proved to be malignant and51
lymphadenectomies were carried out (6).52
With our patient series, we wanted to examine the detection rate and locations of SNs by conventional53
tracers (blue dye and radioisotope) in patients with suspicious ovarian masses. We also aimed to evaluate54
the reliability of SN method in predicting regional lymph node metastasis, in case the mass proved to be55
malignant in frozen section analysis.56
Materials	and	Methods	57
58
From December 2010 through September 2013, 20 eligible women with either unilateral or bilateral59
ovarian masses were recruited to the study. The inclusion criteria were as follows: scheduled open surgery60
(total abdominal hysterectomy TAH and bilateral salpingo-oophorectomy BSO) to remove the suspicious61
mass(es), which was estimated to involve the ovary/adnex only. In premenopausal women with intact62
uterus, also a negative pregnancy test within 24 hours before surgery was required. The exclusion criteria63
were as follows: previous allergic reaction to blue dye or human albumin, and signs of malignant spread to64
the abdominal cavity in preoperative imaging. Ascites alone and/or elevated serum CA 125 without any65
other sign of dissemination were not exclusive.66
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The patient demographics, previous operative history and the largest diameter of the ovarian tumor(s)67
from each patient were recorded.68
In the beginning of each laparotomy, the adnexal mass (or masses) was exposed. This sometimes required69
liberation of adhesions and/or lifting the large tumor outside the abdominal cavity. Then, 1 ml of70
99mTechnetium-labelled human albumin colloid (Nanocoll®, GE Heathcare, Saluggia, Italy) was slowly71
injected to one spot under the serosa next to the lateral junction of the ovarian tumor (mesovarium) with a72
27-gauge needle (Figure 1). The preparation of the radiopharmaceutical was performed in the Department73
of Nuclear Medicine on the same day. The needle was then kept in its place, the syringe changed and 2 ml74
of patent blue dye (Bleu Patenté V®, Guerbet, Paris, France) was injected to the same spot, to prevent the75
tracers to spill out from multiple needle holes and stain the operation field. In the case of bilateral tumors,76
the tracers were injected to both sides.77
78
79
80
81
82
After a minimum of a 10-minute-interval, during which the abdominal cavity was examined, the peritoneal 
cytology taken and the passage of the blue dye noted, the adnexal mass or masses were removed, opened 
and sent to a pathologist for frozen section analysis. After that, the operation was continued with 
hysterectomy (unless previously removed). If the mass was benign or borderline not needing 
lymphadenectomies, the pelvic and paraaortic areas were then closely examined transperitoneally for the 
visible blue dye and extra radiation without opening the peritoneum or removing the nodes. A count 
rate
83
84
85
86
87
88
89
90
91
92
93
 and SN location, using a 
hand-held gamma detector (Neo2000 , Neoprobe, Dublin, Ohio). The number and locations of each blue 
and/or hot spots were marked on a map, that contained all significant lymphatic regions including upper 
paraaortic (PA) and paracaval (PC) area (above inferior mesenteric artery IMA), lower PA/PC area (below 
IMA), right and left common iliac area (upper pelvic area), right and left external iliac area and right and left 
obturator  area  (lower  pelvic  area),  as  well  as  the  method  of  their  detection.  In  the  cas e of  a  borderline  
tumor, a complete surgical staging (CSS; peritoneal biopsies, omentectomy, appendicectomy) was then 
performed.  If the tumor was malignant, systematic pelvic and paraaortic lymphadenectomies were carried 
out as a part of CSS, when technically possible. After opening the peritoneum, all retroperitoneally 
detected SNs (hot and/or blue) were sampled separately and their location marked on the map similarly as 
above.94
The non-SNs were processed according to a standard protocol for lymph node examination; they were cut95
into single sections or, if more than 1 cm in diameter, into 2-3 sections and stained with hematoxylin and96
eosin (H&E) before microscopy. The SNs were cut into 2 mm sections for H&E staining. Ultrastaging and97
immunohistochemistry were not used. All detected metastases and their locations were recorded, and the98
status of each SN was compared to the status of the non-SNs in the same region.99
 was used to estimate the association between tumor size and SN number.100
A p-value less than 0.05  considered statistically significant.101
The study protocol was approved by the local Ethics Committee of Pirkanmaa Hospital District (approval102
number R10072). A written informed consent was obtained from all patients.103
Results	104
Twenty women, median age of 63.3 years (range 41.1-80.7 years) and BMI of 25.8 (range 21.5-36.1), were105
enrolled. The patient data is shown in Table 1. In women with previous open surgeries, a careful liberation106
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of adhesions had to be made before the injection site was properly exposed. Two tumors were torquated107
(patients #12, #18) and the latter also buried under adhesions requiring liberation. The distribution of the108
tumor aspects is shown in Table 2. The median preoperative diameter of the right-sided tumors was 11 cm109
(range 5-20 cm) and that of the left-sided tumors 7 cm (range 3.5-21 cm). One right-sided tumor was found110
to be ruptured, and according to the symptoms of the patient, that had happened the night before surgery.111
Both tracers were successfully injected as described above to all 20 women, and no adverse or allergic112
reactions were noted. The median injected activity of Nanocoll® to one side was 20.0 MBq (range 17.0-26.6113
MBq). The median interval between the tracer injections and the beginning of the removal of the tumor(s)114
was 12 minutes (range 10-33 minutes).115
During the operation, eleven women had benign frozen sections, and the final histopathological116
examination confirmed those results. Four women had borderline tumors. In one case (patient #17), the117
pathologist could not exclude invasion based on the frozen section. As there were also palpable prominent118
lymph nodes on the right paraaortic region, systematic lymphadenectomies were carried out and 3 hot and119
blue SNs were found and sampled on that area. The final diagnosis was serous borderline tumor, with120
endosalpingiosis present in two out of three SNs.121
Five women had a malignant disease (patients #7, #8, #15, #16, #20).  During the examination of the122
abdominal cavity, an unexpected carcinosis was found in two of them (#8 and #16). Patient #8 had a final123
diagnosis of serous ovarian cancer FIGO stage 3a2 with suboptimal surgical result, and #16 had a breast124
cancer metastasis in the right ovary, spreading to the abdominal cavity. In both, SN locations (1 and 3,125
respectively) were transperitoneally detected and mapped. Patient #20 had a BMI of 36.1, and because of126
technical difficulties, the lymphadenectomies were passed, but one hot SN location was found and127
mapped. Altogether, systematic lymphadenectomies with separate SN samplings were performed to 3128
patients (15 % of study population), and in the rest of the patients, a transperitoneal SN mapping was129
carried out.130
We were able to locate 1-3 SNs (median of 2) from each woman, resulting in total of 36 SN sites. For both131
right and left-sided tumors, the mean number of SNs was 2, with a range of 1-3 and 1-2, respectively. In the132
case of bilateral tumors, the median number of SNs was 2 (range 2-3). There was no correlation between133
the size of the tumor and the number of detected SN sites per patient (r2 =0.0012, two-sided p=1.00). In 12134
patients  (60 %),  more than one SN was found,  and in  10 cases  (83 %)  they were located in  the separate135
anatomical regions. The distribution of SN locations and laterality according to the tumor side is shown in136
Table  2.  In  eighteen  patients  with  unilateral  tumors,  most  of  the  SN  sites  were  ipsilateral  (83  %,  15137
patients),  and  contralateral  only  in  one  patient  (6  %),  while  bilateral  SN  sites  were  found  in  11  %  (2138
patients). With bilateral ovarian masses, all the SN sites were detected bilaterally.139
The  regional  distributions  of  all  SNs  are  shown  in  Figure  2.  Seventy-eight  percent  of  all  SN  sites  (28/36)140
were located in the PA region. In 12/20 patients (60 %), it was the only region where SNs were detected. In141
6 (30%) of patients, both PA and pelvic SN locations were seen together. In only two patients (10 %), the142
SNs were found solely in pelvis.143
The left-ovary-related SN sites seemed to be located higher than those related to the right ovary; 64 % vs.144
30 % were located above the IMA, respectively. While 18 % of the left-ovary-related SN sites were traced to145
the upper pelvic (common iliac) region, no SN sites were found in the lower pelvic area. Ten percent of the146
right-ovary-related SN sites were found in the upper pelvic region (common iliac region) and 10 % in the147
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lower  pelvic  region.  The tracers  seemed to cross  the midline from left  to  right  only  above the IMA level,148
whereas crossover from right to left was observed in the upper pelvic, lower PA and upper PA regions.149
The results of the three patients with systematic lymphadenectomies are shown in Table 3.150
Eighteen of all SNs (50 %) were detected both visually and with gamma detector, 17 (47 %) by means of151
radiation only and one (3 %) only visually. With transperitoneal mapping (28 SN locations), 43 % (12 SNs)152
were found by combining dye and radiotracer, 54 % (15 SNs) with radiation only and 4 % (1 SN) with dye153
only. Eight SNs were collected in lymphadenectomised patients, 75 % (6 SNs) with combined method and154
25 % (2 SNs) by using gamma detector. The median intervals between injections and identification of SNs155
were 56 minutes (28-126 minutes) transperitoneally and 129 minutes (49-180 minutes) retroperitoneally.156
Discussion	157
With a detection rate of 100 %, our results confirm that blue dye and radioisotope are swiftly transported158
from the mesovarium to the regional lymph nodes, and that perioperative SN mapping is feasible in159
patients with ovarian tumors.160
The distribution of SN sites in our study is in line with literature concerning lymph node metastases in161
apparent epithelial ovarian cancer (EOC). According to a review with more than 1200 EOC cases, para-aortic162
metastases alone were found in 50 % of patients, both para-aortic and pelvic metastases in 30 % of patients163
and pelvic metastases alone in 20 % of patients. In case of a unilateral tumor, 56 % of the metastases were164
ipsilateral, 21 % contralateral and 41 % bilateral (2).165
In the present study, the left-ovary-related SNs were located either in the PA (71 %) or PA and upper pelvic166
(29 %) areas, whereas the right-ovary related SNs were located PA (64 %), PA and pelvic (18 %) or solely167
pelvic (18 %) areas, including also lower pelvis. The left-ovary-related SNs were more often found above the168
IMA level than the right-ovary-related SNs (64 vs. 30%, respectively). With unilateral tumors, unilateral SNs169
were more common than bilateral SNs (89 vs. 11 %). Nyberg et al. reported 64% of the left-ovary-related170
SNs to be located above the IMA level, while 94 % of the right-ovary-related SNs were located below the171
IMA level. In that series no bi- or contralateral SNs were found (5). Kleppe et al. reported most of their SN172
locations being traced to PA/PC region (67 %), as only 9 % were traced to pelvis and 24 % to both regions.173
Ninety-three percent of SN locations were ipsilateral. In their study, half of transperitoneally detected SN174
sites  related to  the left  ovary  were located in  the ipsilateral  upper  PA area,  compared to  45 % of  the SN175
sites related to the right ovary. All their removed SNs after left-sided injections were found high in the176
upper  left  PA area,  but  the SNs after  right-sided injections  were mainly  located at  the IMA level  (6).  This177
asymmetry, present in all three studies, may be a reflection of the asymmetrical drainage of the right and178
left ovarian veins.179
It has been purported that the tracers should be injected to the both ovarian ligaments (6,7). According to a180
recent paper, three lymphatic drainage pathways from the ovaries can be distinguished. The two main181
routes drain the ovaries via the suspensory ligament toward the PA/PC areas, and via the proper ligament182
of the ovaries toward the obturator fossa and the internal iliac artery. The third minor pathway drains the183
ovaries via the round ligament to the inguinal lymph nodes, but is probably present only in small184
percentage of people. This study did not find any connections between right and left ovarian drainage, nor185
did it explain the asymmetry of lymphatic networks between right and left ovary. It however described that186
a considerable number of lymphatic vessels are present in mesovarium along the entire length of the ovary187
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(7). To our experience, the tracers leak out from the tiniest holes and smudge the operation field,188
hampering the visibility of blue-stained lymphatics and the use of gamma detector in pelvis. Our one-spot189
injection to the mesovarium gave similar SN distribution results compared to the study by Kleppe et al. (6),190
although they injected the tracers to both ovarian ligaments. Although one should be cautious in making191
firm conclusions based on small materials, it seems unnecessary to use multiple injection spots.192
In present study, blue dye was observed transperitoneally in less than half of the cases. Retroperitoneally193
explored, 75 % of the hot nodes were also blue-stained. In the study of Kleppe et al., blue staining was not194
recorded at all in transperitoneal mapping. In retroperitoneal exploration, they identified blue dye only in195
one third of the patients (6). The visibility of blue dye depends on the interval between the injection and196
mapping and the thickness of the tissue around the lymphatic vessels. To our experience, blue dye shows197
where to seek for the radiation. However, a lack of blue staining does not exclude the possibility of hot198
nodes. A new tracer indocyanine green is reported to have an improved tissue penetration compared to199
blue dye. Replacing blue dye with it might enhance the visibility. The results in endometrial and cervical200
cancer have certainly been promising (8,9).201
Only one patient in our series (#15) had lymph node metastases; in PC and right pelvic area. Two SNs were202
found in the lower PC area, one of which was metastatic and predicted correctly the surgical stage of the203
patient. However, there were no SNs detected in the right pelvic area. In the series by Kleppe et al, also one204
patient had lymph node metastases in SNs and in other regional nodes. She, however, had a final diagnosis205
of ovarian and synchronous endometrial cancer, and it was not conclusive which cancer the metastases206
were related to (6). The number of patients studied is still too small to allow for any conclusions about the207
reliability of SN concept in ovarian cancer. When adding our results to the study of Kleppe et al., 41 ovarian208
tumor patients have been operated on, 9 lymphadenectomies have been performed and only two patients209
(5 % of all)  have had lymph node metastasis. Based on the above figures, to collect 20 EOC patients with210
nodal metastasis, one should include approximately 400 ovarian tumor patients. It is not easy to find211
suitable patients with suspicious ovarian tumors but no signs of dissemination. Two of our patients (10 %)212
had more advanced disease than was preoperatively assumed. For us, it took several years to gather a213
series even this large. Obviously only a multicenter study could solve this problem.214
215
216
217
218
219
220
We conclude that perioperative one-spot injection of blue dye and technetium isotope is feasible in 
detecting sentinel nodes in patients with ovarian tumor(s). One to three SNs per patient can be found 
with this method; they are usually ipsilateral, but both bi- and contralateral SN are conceivable. Our 
results confirm that the main lymphatic drainage route from ovary is to PA region, the SNs of the left 
ovary being usually located higher than those of the right ovary. Also, the pelvic SNs related to the left ovary 
seem to be located higher in the pelvis than those related to the right ovary. The reliability of the SN concept 
in ovarian cancer and its clinical applications should be evaluated in a larger multicenter study.221
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Figure	legends	249
250
Figure 1. The injection spot of the tracers to the mesovarium.251
Figure 2. The distribution (percentages and numbers) of sentinel nodes (SN) in all anatomic regions252
according to the injection site: all SNs, right-ovary-related SNs, left-ovary-related SNs, SNs of both ovaries,253
respectively.254
Table 1. The patient demographics. BMI=body mass index, TAH=total abdominal hysterectomy,255
BSO=bilateral salpingo-oophorectomy, SVA=supravaginal uterine amputation, BS=bilateral salpingectomy,256
BO=bilateral oophorectomy, ADH=liberation of adhesions, LAE=pelvic and para-aortic lymphadenectomies,257
OM=omentectomy, APP=appendicectomy, BP=peritoneal biopsies, BOT=borderline ovarian tumor,258
VH=vaginal hysterectomy.259
Table 2. The distribution and laterality of sentinel node locations in 20 patients according to the side of the260
ovarian tumor. Tumor side was also the tracer injection site. SN = sentinel node.261
Table 3. The histopathological results of the retroperitoneal SN sampling and systematic262
lymphadenectomy. PA=paraaortic, SN=sentinel node.263
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